Journal list Promote Sponsor
verified SJR 0,724 · Q2 • database Scopus / SJR & Web of Science indexed
Expert Review of Hematology
United Kingdom · Taylor and Francis Ltd.
workspace_premium Q2 — Hematology lock Subscription

Expert Review of Hematology

Expert Review of Hematology is a journal indexed in SJR in Hematology with an H index of 58. It has a price of 4000 €. It has an SJR impact factor of 0,724 and it has a best quartile of Q2. It has an SJR impact factor of 0,724.

ISSN: 1747-4086
Publisher: Taylor and Francis Ltd.
Category: Hematology
Indexation: verifiedScopus / SJR verifiedWeb of Science
open_in_new Portal NPD menu_book Guidelines NPD
schedule CountryOfPapers database fields
SJR Impact Factor trending_up
0,724 Q2
H-index 58
Acceptance rate pie_chart
32%
Source Acceptance_Rate
Time to publication hourglass_top
NPD
Field NPD
Publication cost (APC) payments
4.000 € Subscription
Non-OA path 0 €

Metrics

Scimago and CountryOfPapers database fields

Scopus / SJR Web of Science

SJR Impact

0,724

H-index

58

Docs (year)

97

Docs 3y

326

Total refs

6940

Cites 3y

724

Citable 3y

299

Cites/Doc 2y

2.02

Ref/Doc

71.55

Immediate OA

4000 €

Embargoed OA

NPD

Non OA / Submission

0 €

shield Researcher voice

Name good journals. Call out predatory ones.

Share what peer review, fees, and timelines were really like. Praise fair editors. Flag APC traps, fake metrics, or spam solicitations — with facts from your submission.

Fair & fast peer review Clear APC / no surprise fees Suspected predatory Fake impact claims
rate_review Write an honest review

Researcher reviews

sentiment_dissatisfied No reviews yet — be the first to share an honest experience.
User
* Only to validate authenticity — identity is not shown publicly.

Best articles by citations

Bone morbidity in chronic myeloproliferative neoplasms

View more

When to treat patients with relapsed follicular lymphoma

View more

Detection of mild inherited disorders of blood coagulation: current options and personal recommendations

View more

Design of the INHIBIT trial: preventing inhibitors by avoiding 'danger', prolonging half-life and promoting tolerance

View more

Decision-making in the management of adult classical Hodgkin's lymphoma: determining the optimal treatment

View more

Darbepoetin alfa for anemia with myelodysplastic syndrome

View more

Current strategies for treatment of relapsed/refractory multiple myeloma

View more

Communications on multiple myeloma

View more

Combining proteasome with cell cycle inhibitors: a dual attack potentially applicable to multiple hematopoietic malignancies

View more

Chimeric antigen receptor T cells: power tools to wipe out leukemia and lymphoma

View more

CD20-negative diffuse large B-cell lymphomas: biology and emerging therapeutic options

View more

Brentuximab vedotin in T-cell lymphoma

View more
SHOW MORE ARTICLES

Bosutinib: a dual SRC/ABL kinase inhibitor for the treatment of chronic myeloid leukemia

View more

2nd International Congress on Leukemia, Lymphoma and Myeloma

View more

Axl inhibition: a potential road to a novel acute myeloid leukemia therapy?

View more

Atherosclerosis, venous thromboembolism and migraine: what are the associated risks?

View more

Antigen-specific immunotherapy for acute myeloid leukemia: where are we now, and where do we go from here?

View more

Anti-infective prophylaxis in pediatric patients with acute myeloid leukemia

View more

Anemia in children: prevalence, causes, diagnostic work-up, and long-term consequences

View more

American Society of Hematology Annual Meeting 2014: highlights in multiple myeloma

View more

Adult T-cell leukemia-lymphoma: current treatment strategies and novel immunological approaches

View more

Adult T-cell acute lymphoblastic leukemia: prognostic impact of myeloid-associated antigens

View more

Acute erythroleukemia: diagnosis and management

View more

A systematic literature review and indirect comparison of iron isomaltoside and ferric carboxymaltose in iron deficiency anemia after failure or intolerance of oral iron treatment

View more

FAQs